Sep 1 2009
Bio-Matrix Scientific Group, Inc. (OTCBB:BMSN) Chairman & CEO David Koos commented on the Company’s new opportunities in stem cell research, cancer treatment and intellectual property. Mr. Koos noted, “In the last 3 months we have made substantial progress in areas we believe will be accretive for our shareholders. It is my belief that our business model is far more balanced and progressive today than we have previously been. The new opportunities on the table for us now should diversify our revenue model and complement each other as the Company grows. We see Entest BioMedical (OTCBB:ENTB) leading the way in expanding the Company’s core business.”
Recent Developments include:
Entering into discussions and due diligence process regarding a potential mutually beneficial business arrangement with a biotech company that is in FDA Fast Track for Phase 3 Clinical Trials on the development of a cancer treatment.
The execution of an agreement with Therinject LLC regarding, among other matters, the development and marketing of a therapeutic cancer vaccine for initial use in veterinary applications as well as the Company’s entry into Tumor Cell Banking.
The filing of a patent application by Entest Biomedical for the use of adipose (fat) derived stem cells in the treatment of Chronic Obstructive Pulmonary Disease (COPD).
Entering into discussions with a biomedical manufacturer to jointly produce a medical device used in diabetes and cancer research.
AI models redefine TIL scoring in breast cancer but face challenges in real-world validation